Compare · MEDP vs PRAH
MEDP vs PRAH
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and PRA Health Sciences, Inc. (PRAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and PRAH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP carries a market cap of $17.55B.
- MEDP has hit the wire 9 times in the past 4 weeks while PRAH has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for PRAH).
- Company
- Medpace Holdings Inc.
- PRA Health Sciences, Inc.
- Price
- $618.31-1.68%
- $165.29-1.68%
- Market cap
- $17.55B
- -
- 1M return
- +0.58%
- -
- 1Y return
- +13.61%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2014
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)
Latest PRAH
- Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
- SEC Form SC 13G filed by PRA Health Sciences, Inc.
- SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)
- SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Young Matthew P. returned 7,127 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Stettin Glen D. returned 1,049 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: MOMTAZEE JAMES C returned 3,521 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Dickinson Alexander George returned 5,407 units of Common Stock to the company, closing all direct ownership in the company